Re: Script count
First of all MNKD is being run by SNY and they aren't saying anything. I'm sure their deal has them pretty much under a non-disclosure that doesn't allow them to talk about the roll out strategy.
Secondly. SNY isn't about to lay out their strategy in a highly competitive market place for diabetes drugs. My statements are 100% factual because you have to be a moron not to be able to read the tea leafs. Did you see the show in Boston with the massive Afrezza sign outside of the SNY booth? Have you followed how many dinner meetings SNY is holding for ENDO's to educate them? Have you seen the recent print ads? Have you seen the insurance coverage increasing? Have you seen the testimonials and new websites? Its pretty easy to follow the road map to what is transpiring and yes bloggers like the recent post on SA have seen it as well.
Lastly can you name one other publicly traded company that gets so many hit pieces published on a weekly basis as MNKD? Its obvious what is transpiring and keep your blinders on about scrip counts and BK gibberish you will never see the train coming until it hits you head on.